Patents by Inventor Kirston E. Koths

Kirston E. Koths has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant PR-3 and assays employing the same
    Patent number: 6599706
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Jan Tuttleman, Carl Perez, David A. Jewell, Kirston E. Koths
  • Recombinant PR-3 and compositions thereof
    Patent number: 6586222
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • DNA encoding N?2 CSF-1 (short form) and carboxy truncated fragment thereof
    Patent number: 6204020
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both “long” and “short” forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: March 20, 2001
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof
    Patent number: 6156300
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 5, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding NV2 (long form) and carboxy truncated fragments thereof
    Patent number: 6146851
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: November 14, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof
    Patent number: 6117422
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof
    Patent number: 6103224
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 15, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Secreted mac-2-binding glycoprotein
    Patent number: 6069127
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approtely 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 30, 2000
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • Compositions for the inhibition of TNF hormone formation and uses thereof
    Patent number: 5998378
    Abstract: Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kDProTNF, and methods for identifying compounds having the desired inhibitory activity are provided.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: December 7, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez, Robert F. Halenbeck, David A. Jewell, Kirston E. Koths
  • Nucleic acid encoding secreted Mac-2 binding glycoprotein
    Patent number: 5965382
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • Assay method for screening for inhibitors of proTNF conversion
    Patent number: 5843693
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF.alpha.. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF.alpha. to its mature active form.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: December 1, 1998
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Secreted Mac-2-binding glycoprotein
    Patent number: 5736340
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for reagents that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system, and for monitoring the concentration of the glycoprotein in human milk.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 7, 1998
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
    Patent number: 5681719
    Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N- 3 deletion mutants of the long form of CSF-1
    Patent number: 5672343
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 30, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Method for purifying secreted Mac-2-binding glycoprotein
    Patent number: 5644035
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 1, 1997
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • N-.gradient.3 deletion mutants of the short form of CSF-1
    Patent number: 5643563
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: July 1, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding various forms of colony stimulating factor-1
    Patent number: 5573930
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: November 12, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Monoclonal antibodies that bind to and neutralize dimeric but not monomeric human M-CSF and methods of use thereof for detection of dimeric M-CSF
    Patent number: 5491065
    Abstract: Monoclonal antibodies that bind to an apparent conformational epitope associated with recombinant or native dimeric M-CSF with concomitant neutralization of biological activity, which monoclonal antibodies are substantially unreactive with biologically inactive forms of M-CSF including monomeric and chemically derivatized dimeric M-CSF, are described. Methods of using the antibodies in assays for detection of dimeric M-CSF are also described.
    Type: Grant
    Filed: November 19, 1993
    Date of Patent: February 13, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Robert F. Halenbeck, Kirston E. Koths, Joseph W. Wrin
  • Compositions for detecting ras gene proteins and cancer therapeutics
    Patent number: 5234839
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: August 10, 1993
    Assignee: Cetus Oncology Corporation
    Inventors: Frank P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
  • Compositions for detecting ras gene proteins and cancer therapeutics
    Patent number: RE35171
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: March 5, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey